Category: St. Jude Medical
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.
MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
Medtronic's Symplicity renal denervation device for hypertension lowered blood pressure only slightly more than patients treated with drugs and a sham procedure, the company said Saturday at the American College of Cardiology's annual conference.
Medtronic (NYSE:MDT) revealed the details of a clinical trial of its Symplicity renal denervation treatment for hypertension, but said it still plans to investigate the treatment even though the study showed only meager improvements in high blood pressure compared with a sham procedure.
A small European feasibility study of the Nanostim leadless pacemaker acquired by St. Jude Medical looks good at 3 months, according to a study published in the American Heart Assn. journal Circulation.
The Nanostim leadless pacemaker acquired by St. Jude Medical (NYSE:STJ) last year appeared safe and functional after 3 months, according to results of a small study published in the American Heart Assn. journal Circulation.
A new editorial in the Annals of Internal Medicine criticizes the premarket approval modification process, through which both Medtronic and St. Jude Medical released high-risk products that were later recalled.
The FDA grants pre-market approval to St. Jude Medical's Allure Quadra cardiac resynchronization therapy pacemaker.
St. Jude Medical (NYSE:STJ) said its Allure Quadra pacemaker will be the 1st on the U.S. market to offer quadripolar cardiac resynchronization therapy after the FDA granted pre-market approval to the device.
Here's a look at some of the top legal news stories for medical device companies this week.